Chenodeoxycholic Acid Leadiant Labeling Update
Annual reviews of new information will be conducted to update the summary, requiring continuous monitoring and data submission in response to findings.
Primary source: Cancellation of Notified Cosmetic Products
The updated list identifies cosmetic manufacturers verified to meet GMP standards as of August 10, 2026.
This list impacts compliance and regulatory oversight for cosmetic products in Malaysia, guiding stakeholders towards approved manufacturers and enhancing consumer safety.
Review and verify that any cosmetic products sourced or distributed comply with the manufacturers listed in the updated QUEST system.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Review and verify that any cosmetic products sourced or distributed comply with the manufacturers listed in the updated QUEST system.
The National Pharmaceutical Regulatory Agency (NPRA) in Malaysia released an updated list of cosmetic manufacturers that comply with Good Manufacturing Practice (GMP) requirements according to ASEAN guidelines. This list is crucial for ensuring that only compliant entities are allowed to operate within the cosmetic sector in Malaysia.
What changed: The updated list identifies cosmetic manufacturers verified to meet GMP standards as of August 10, 2026.
Why it matters: This list impacts compliance and regulatory oversight for cosmetic products in Malaysia, guiding stakeholders towards approved manufacturers and enhancing consumer safety.
Practical implication: Review and verify that any cosmetic products sourced or distributed comply with the manufacturers listed in the updated QUEST system.
Published from the regulator source ingestion pipeline after PV impact triage.
Annual reviews of new information will be conducted to update the summary, requiring continuous monitoring and data submission in response to findings.
Marketing authorization holders (MAHs) must review and potentially update their product labeling to align with the new regulations by 11 April 2029 for products authorized before 11 May 2024.
Healthcare organizations should review the NPRA annual report to ensure compliance with updated safety monitoring practices and adjust their reporting and signal management processes accordingly.
Regulatory Intelligence Leads must incorporate the new reporting requirements and deadlines into their monitoring activities for affected products.